PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Ribas Latre, A. ; Hoffmann, A. ; Gebhardt, C. ; Weiner, J.* ; Arndt, L.* ; Raulien, N.* ; Gericke, M.* ; Ghosh, A.* ; Krause, K.* ; Klöting, N. ; Pfluger, P.T. ; Sheikh, B. ; Ebert, T.* ; Tönjes, A.* ; Stumvoll, M. ; Wolfrum, C.* ; Blüher, M. ; Wagner, U.* ; Vendrell, J.* ; Fernández-Veledo, S.* ; Heiker, J.T.

The serine protease KLK7 promotes immune cell infiltration in visceral adipose tissue in obesity.

Metabolism 168:156239 (2025)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Obesity is a major health problem associated with global metabolic dysfunction and increased inflammation. It is thus critical to identify the mechanisms underlying the crosstalk between immune cells and adipose tissue that drive cardiovascular and metabolic dysfunction in obesity. Expression of the kallikrein-related serine protease 7 (KLK7) in adipose tissue is linked to inflammation and insulin resistance in high fat diet (HFD)-fed mice. Here, we engineered mice with a macrophage-specific KLK7 knockout (KLK7MKO) to investigate how KLK7 loss impacts immune cell function and obesity-related pathology. Compared to control mice, we observed lower levels of systemic inflammation, with less infiltration and activation of inflammatory macrophages in HFD-fed KLK7MKO mice, particularly in the epididymal adipose tissue. Mechanistically, we uncover that Klk7 deficiency reduces pro-inflammatory gene expression in macrophages and restricts their migration through higher cell adhesion, hallmark features of macrophages in obese conditions. Importantly, through analyses of 1143 human visceral adipose tissue samples, we uncover that KLK7 expression is associated with pathways controlling cellular migration and inflammatory gene expression. In addition, serum KLK7 levels were strongly correlated with circulating inflammatory markers in a second cohort of 60 patients with obesity and diabetes. Our work uncovers the pro-inflammatory role of KLK7 in controlling inflammatory macrophage polarization and infiltration in visceral obesity, thereby contributing to metabolic disease. Thus, targeting KLK7 to control immune cell activation may dissociate adipose dysfunction from obesity, thereby representing an alternative obesity therapy.
Impact Factor
Scopus SNIP
Altmetric
11.900
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Adipose Tissue ; Inflammation ; Metabolic Disease ; Obesity ; Protease ; Serpin; Kallikrein 7; Tenascin-c; 3t3-l1 Adipocytes; Gene-expression; Morbid-obesity; Inflammation; Vaspin; Skin; Fibronectin; Inhibition
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0026-0495
e-ISSN 1532-8600
Zeitschrift Metabolism: clinical and experimental
Quellenangaben Band: 168, Heft: , Seiten: , Artikelnummer: 156239 Supplement: ,
Verlag Elsevier
Verlagsort 1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, Pa 19103-2899 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-554800-001
G-506501-001
G-506500-001
G-502294-001
G-555000-001
Förderungen Generalitat de Catalunya
German Federal Ministry of Health (Berlin, Germany)
German Diabetes Association (DDG)
AstraZeneca
EFSD Mentorship Programme
Helmholtz Munich
Free State of Saxony
German Research Foundation)
Ministry of Culture and Science of the state North Rhine-Westphalia (Duesseldorf, Germany)
German Federal Ministry of Education and Research (BMBF) through the German Center for Diabetes Research
Agency for Management of University
Ministerio de Ciencia e Innovacion
Instituto de Salud Carlos III
CIBER-Consorcio Centro de Investigacion Biomedica en Red
The "La Caixa" Foundation
Spanish Ministry of Science and Innovation MCIN/AEI
European Research Council (ERC CoG)
Deutsche Forschungsgemeinschaft (DFG
DOI 10.1016/j.metabol.2025.156239
WOS ID 001460500700001
Scopus ID 105001251142
PubMed ID 40154838
Erfassungsdatum 2025-05-09
[➜Korrektur melden]